MedTrace Logo

Trilogy Stereotactic Body Radiotherapy for Pancreatic Cancer

NCT00350142 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-02-14

Study results available
· View outcomes & findings →

Summary

This study will assess the efficacy of treating locally advanced pancreatic cancer using Stereotactic Body Radiotherapy (using Trilogy) and Gemcitabine

Conditions

Interventions

RADIATION

Stereotactic Body Radiotherapy

Stereotactic Body Radiotherapy will be performed using Trilogy Linear Accelerator

DRUG

Gemcitabine

Weekly Gemcitabine will be administered at 1000mg/m2 over 100 minutes

OTHER

4D pancreatic protocol CT scan

Patients will undergo this imaging procedure prior to treatment for planning purposes.

RADIATION

FDG PET scan

Patients will have this imaging procedure along with a CT scan to map the tumor and facilitate treatment planning.

Sponsors & Collaborators

  • Albert Koong

    lead OTHER

Principal Investigators

  • Albert Koong · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2008-10-31
Completion
2008-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00350142 on ClinicalTrials.gov